Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Clown-Free Zone... sorry, no clowns allowed -- Ignore unavailable to you. Want to Upgrade?

To: mishedlo who wrote (124960)	9/22/2001 6:40:51 PM
From: Joan Osland Graffius	Read Replies (2) \| Respond to of 436258

mishedio, >>I line INCY better because the stock price is close to cash on hand. I do to. I will look at BMET. It is very hard to find these research bio techs that are profitable, but at this point in time the technology they own is what is important as it used by the big pharams to conduct the research. I think the companies that have technology which are critical to the research will be the winners in the long run. They will share in the profits of the Billion $ drugs that come out of the research. I can not figure out which bio techs will be the big winners. Therefore buying cheap and selling high is the name of the game at the moment. If some one wants to take a long term approach in the sector I would recommend HQH. I have purchased this for my daughters IRA. She has 20 some odd years before she retires and if the growth story stays the same in this sector this CEF should do well. We add to her positions when the CEF is dirt cheap and have the dividends reinvested. I can not come up with any sector that has a long term growth story at the moment. Do you know of one? If so I am interested in your thoughts. Joan